Table 5.
Response of CLL/SLL by Treatment in Patients With or Without Other Malignant Neoplasms
| Variable | Treated Patients | F ± P |
FM |
FC |
FCR/R-FCM/R-FND |
R ± GM |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | No. | % | ||
| No. of patients treated | 931 | 167 | 49 | 117 | 476 | 122 | |||||
| CR | 452 | 52 | 31 | 17 | 35 | 44 | 38 | 328 | 69 | 11 | 9 |
| Overall response | 845 | 150 | 90 | 42 | 86 | 103 | 88 | 455 | 96 | 95 | 78 |
| Median follow-up, years | 4.3 | 14.3 | 10.3 | 7.6 | 3.2 | 1.4 | |||||
| Had other cancer before CLL/SLL therapy | 127 | 16 | 9.6 | 7 | 14.3 | 17 | 14.5 | 66 | 13.9 | 21 | 17.2 |
| Developed other cancer only after CLL/SLL therapy | 138 | 44 | 26.3 | 9 | 18.4 | 24 | 20.5 | 55 | 11.6 | 6 | 4.9 |
| No other cancer | 666 | 107 | 64.1 | 33 | 67.4 | 76 | 65.0 | 355 | 74.6 | 95 | 77.9 |
Abbreviations: CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; F ± P, fludarabine, with or without prednisone; FM, fludarabine and mitoxantrone; FC, fludarabine and cyclophosphamide; FCR, fludarabine, cyclophosphamide, and rituximab; R-FCM, fludarabine, cyclophosphamide, mitoxantrone, and rituximab; R-FND, fludarabine, mitoxantrone, dexamethasone, and rituximab; R ± GM, rituximab, with or without granulocyte-macrophage colony-stimulating factor; CR, complete response.